Vida Ventures
VC Fund
Boston, United States
Vida Ventures is a VC fund in Boston focused on Biotechnology and Health Care. Vida Ventures’ mission is to bring science to life by advancing transformative biomedical innovations that have the potential to make a meaningful impact on the lives of patients. They want to do well by doing good for others. Vida Ventures is a bicoastal life sciences company building and investment firm, founded in 2017 by a group of scientists,physicians, entrepreneurs, and investors who are passionate about building and funding breakthroughs in biomedicine .
- Total investments:
- 74
- Last investment:
- Lead investor:
- 36%
- Fund size:
- $825M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Vida Ventures invests in
Stages Vida Ventures invests in
Countries Vida Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 9 contacts → | |||
Round size
- Series A
- $35M–$310M
- Series B
- $60M–$175M
- Series C
- $60M–$175M
Investment Focus
Industry
- Biotechnology 40 (54%)
- Health Care 24 (32%)
- Medical 19 (26%)
- Therapeutics 18 (24%)
- Pharmaceutical 13 (18%)
Stage
- Series A 23 (31%)
- Series B 17 (23%)
- Series C 9 (12%)
- Seed 6 (8%)
- Series D 2 (3%)
Country
- United States 40 (54%)
- China 1 (1%)
- India 1 (1%)
- France 1 (1%)
- Denmark 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Fred Cohen
Co-Founder & Sr. Managing Director
|
Co-Founder & Sr. Managing Director | Total investments: 13 | Find email | |
Helen Kim
Senior Managing Director
|
Senior Managing Director | Total investments: 8 | Find email | |
Mark Springel
Associate
|
Associate | Total investments: 0 | Find email | |
Arie Belldegrun
Co-Founder & Senior Managing Director; Founding Partner
|
Co-Founder & Senior Managing Director; Founding Partner | Total investments: 6 | Find email | |
Arjun Goyal
Co-Founder and Managing Director
|
Co-Founder and Managing Director | Total investments: 13 | Find email | |
| See all 9 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| SonoThera is a biotechnology company that creates non-viral genetic therapies using ultrasound. Its mission is to develop genetic medicines that treat the root cause of human disease. SonoThera is expanding the possibilities of disease treatment with ultrasound-guided nonviral gene therapy for diseases with suboptimal or non-existent treatments. Itaims to improve the lives and health of millions of people. | $125M / Series B / Jun 10, 2026 | ||
| ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment. | $75M / Series C / Apr 14, 2026 | ||
| Poplar Therapeutics anti-IgE therapy treats atopic diseases such as food allergy, allergic asthma, and atopic dermatitis. | $50M / Series A / Jan 07, 2026 | ||
| Protego Biopharma develops therapeutics based on the clear human genetic link, excellent human safety profile, proof-of-principle efficacy. The company was founded in 2011 and is headquartered in San Diego, California. | $130M / Series B / Dec 01, 2025 | ||
| Avalyn Pharma is a biopharma company that advances therapies for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other severe respiratory diseases. Its therapies rapidly advance AP01 for the treatment of IPF, provides additional pipeline candidates for IPF, improve the care and outcomes of severe respiratory diseases, and develop novelinhaled therapeutics.Avalyn Pharma was established in 2011 and is headquartered in Seattle, Washington. | $100M / Series D / Jul 22, 2025 | ||
| Antares Therapeutics is a biotechnology company focused on developing transformational precision medicines targeting validated but previously undruggable targets in cancer and other serious diseases with significant unmet medical needs. Founded as a spin-out from Scorpion Therapeutics, it leverages proprietary drug discovery capabilities and arobust preclinical pipeline to advance multiple programs, primarily in precision oncology. | $177M / Series A / May 15, 2025 | ||
Attovia Therapeutics
|
Attovia Therapeutics is a biotherapeutics pipeline developer focused on immune-mediated illness and oncology. The company uses the nanobody platform to create tiny format binders with low picomolar affinity, increased selectivity, quicker internalization, and rapid tissue penetration, thereby assisting cancer patients in being treated. | $90M / Series C / Apr 15, 2025 | |
| Soufflé Therapeutics is a biotechnology company specializing in the development of nucleic acid medicines designed for precise delivery and targeting of disease-causing cells. The company's mission is to create potent, precise, and safe medicines that can be tailored for a broad range of diseases by leveraging breakthroughs in genetic medicineand drug delivery technology. | $200M / Series A / Jan 01, 2025 | ||
| Candid Therapeutics is a biotechnology company that focuses on the treatment of a range of immunological conditions. | $370M / Series B / Sep 09, 2024 | ||
Halda Therapeutics
|
Halda Therapeutics is a research-stage drug discovery company, seeking to create the next generation of precision medicine based on a novel therapeutic modality which may be a platform for a number of disease states. | $126M / Series B / Aug 12, 2024 | |
| See all 74 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Vida Ventures invest in?
Vida Ventures invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Series B stage. Most of the 74 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Vida Ventures's check size?
Vida Ventures typically joins rounds of $35M–$310M at Series A, $60M–$175M at Series B and $60M–$175M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Vida Ventures participates in.
How do I contact Vida Ventures?
Public channels for Vida Ventures include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Vida Ventures?
The team at Vida Ventures includes Fred Cohen (Co-Founder & Sr. Managing Director), Helen Kim (Senior Managing Director) and Mark Springel (Associate), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
